| Year |
Citation |
Score |
| 2023 |
Imam MZ, Kuo A, Ghassabian S, Cai Y, Qin Y, Li T, Smith MT. CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats. Pharmacological Reports : Pr. PMID 36637684 DOI: 10.1007/s43440-023-00446-8 |
0.311 |
|
| 2022 |
Smith MT, Kong D, Kuo A, Imam MZ, Williams CM. Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources. Journal of Medicinal Chemistry. PMID 34995453 DOI: 10.1021/acs.jmedchem.0c01915 |
0.315 |
|
| 2020 |
Park TSW, Khan N, Kuo A, Nicholson JR, Corradini L, Smith MT. Characterisation of a rat model of mechanical low back pain at an advanced stage using immunohistochemical methods. Clinical and Experimental Pharmacology & Physiology. PMID 32888350 DOI: 10.1111/1440-1681.13402 |
0.306 |
|
| 2020 |
Imam MZ, Kuo A, Nicholson JR, Corradini L, Smith MT. Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain. Pharmacological Reports : Pr. PMID 32715433 DOI: 10.1007/S43440-020-00145-8 |
0.318 |
|
| 2020 |
Imam MZ, Kuo A, Smith MT. Countering opioid-induced respiratory depression by non-opioids that are respiratory stimulants. F1000research. 9. PMID 32089833 DOI: 10.12688/F1000Research.21738.1 |
0.387 |
|
| 2020 |
Kuo A, Magiera J, Rethwan N, Andersson Å, Leen Lam A, Wyse B, Meutermans W, Lewis R, Smith M. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile. European Journal of Pharmacology. 172947. PMID 31991138 DOI: 10.1016/J.Ejphar.2020.172947 |
0.328 |
|
| 2020 |
Imam MZ, Kuo A, Ghassabian S, Cai Y, Qin Y, Li T, Smith MT. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine. European Journal of Pharmacology. 172918. PMID 31958457 DOI: 10.1016/J.Ejphar.2020.172918 |
0.423 |
|
| 2019 |
Shenoy PA, Kuo A, Leparc G, Hildebrandt T, Rust W, Nicholson JR, Corradini L, Vetter I, Smith MT. Transcriptomic characterisation of the optimised rat model of Walker 256 breast cancer cell-induced bone pain. Clinical and Experimental Pharmacology & Physiology. PMID 31429474 DOI: 10.1111/1440-1681.13165 |
0.326 |
|
| 2019 |
Park TSW, Khan N, Kuo A, Nicholson JR, Corradini L, Smith MT. J-2156, a somatostatin receptor type 4 agonist, alleviates mechanical hyperalgesia in a rat model of chronic low back pain. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 117: 109056. PMID 31181441 DOI: 10.1016/J.Biopha.2019.109056 |
0.367 |
|
| 2019 |
Huang L, Wyse BD, Williams CM, Smith MT. Nitric Oxide Modulates μ-Opioid (MOP) Receptor Function In Vitro. Clinical and Experimental Pharmacology & Physiology. PMID 30933370 DOI: 10.1111/1440-1681.13091 |
0.43 |
|
| 2019 |
Zhu M, Whittaker AK, Smith MT, Han FY. Bioerodable Ketamine-Loaded Microparticles Fabricated Using Dissolvable Hydrogel Template Technology. Journal of Pharmaceutical Sciences. 108: 1220-1226. PMID 30773202 DOI: 10.1016/J.Xphs.2018.10.029 |
0.365 |
|
| 2019 |
Kuo A, Nicholson JR, Corradini L, Smith MT. Establishment and characterisation of a stavudine (d4T)-induced rat model of antiretroviral toxic neuropathy (ATN) using behavioural and pharmacological methods. Inflammopharmacology. PMID 30600474 DOI: 10.1007/S10787-018-00551-8 |
0.388 |
|
| 2018 |
Han FY, Whittaker AK, Howdle SM, Naylor A, Shabir-Ahmed A, Zhang C, Smith MT. Formulation of Bioerodible Ketamine Microparticles as an Analgesic Adjuvant Treatment Produced by Supercritical Fluid Polymer Encapsulation. Pharmaceutics. 10. PMID 30563294 DOI: 10.3390/Pharmaceutics10040264 |
0.343 |
|
| 2018 |
Han FY, Whittaker A, Howdle SM, Naylor A, Shabir-Ahmed A, Smith MT. Sustained-Release Hydromorphone Microparticles Produced by Supercritical Fluid Polymer Encapsulation. Journal of Pharmaceutical Sciences. PMID 30267781 DOI: 10.1016/J.Xphs.2018.09.021 |
0.313 |
|
| 2018 |
Qin Y, Ni L, Shi J, Zhu Z, Shi S, Lam AL, Magiera J, Sekar S, Kuo A, Smith MT, Li T. Synthesis and biological evaluation of fentanyl analogues modified at phenyl groups with alkyls. Acs Chemical Neuroscience. PMID 30179508 DOI: 10.1021/Acschemneuro.8B00363 |
0.351 |
|
| 2018 |
Shenoy PA, Kuo A, Khan N, Gorham L, Nicholson JR, Corradini L, Vetter I, Smith MT. The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Frontiers in Pharmacology. 9: 495. PMID 29867498 DOI: 10.3389/Fphar.2018.00495 |
0.383 |
|
| 2018 |
Kuo A, Smith MT. In Vivo Profiling of Four Centrally Administered Opioids for Antinociception, Constipation and Respiratory Depression: Between Colony Differences in Sprague Dawley Rats. Clinical and Experimental Pharmacology & Physiology. PMID 29786873 DOI: 10.1111/1440-1681.12972 |
0.388 |
|
| 2018 |
Han FY, Kuo A, Nicholson JR, Corradinni L, Smith MT. Comparative Analgesic Efficacy of Pregabalin Administered According to Either a Prevention Protocol or an Intervention Protocol in Rats with Cisplatin-induced Peripheral Neuropathy. Clinical and Experimental Pharmacology & Physiology. PMID 29781509 DOI: 10.1111/1440-1681.12971 |
0.365 |
|
| 2018 |
Park TSW, Kuo A, Smith MT. Chronic low back pain: a mini-review on pharmacological management and pathophysiological insights from clinical and pre-clinical data. Inflammopharmacology. PMID 29754321 DOI: 10.1007/S10787-018-0493-X |
0.323 |
|
| 2017 |
Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology. 131: 238-255. PMID 29273520 DOI: 10.1016/J.Neuropharm.2017.12.032 |
0.4 |
|
| 2017 |
Khan N, Muralidharan A, Smith MT. Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia - A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) Receptor Antagonist. Frontiers in Molecular Neuroscience. 10: 389. PMID 29200998 DOI: 10.3389/Fnmol.2017.00389 |
0.325 |
|
| 2017 |
Khan N, Kuo A, Brockman DA, Cooper MA, Smith MT. Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. Inflammopharmacology. PMID 28965161 DOI: 10.1007/S10787-017-0401-9 |
0.368 |
|
| 2017 |
Lotfipour S, Smith MT. Morphine hyposensitivity in STZ-diabetic rats: Reversal by dietary L-arginine treatment. Clinical and Experimental Pharmacology & Physiology. PMID 28925511 DOI: 10.1111/1440-1681.12855 |
0.629 |
|
| 2017 |
Muralidharan A, Park TSW, Mackie JT, Gimenez LGS, Kuo A, Nicholson JR, Corradini L, Smith MT. Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods. Frontiers in Pharmacology. 8: 493. PMID 28798688 DOI: 10.3389/Fphar.2017.00493 |
0.338 |
|
| 2017 |
Shenoy P, Kuo A, Vetter I, Smith MT. Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological Methods. Frontiers in Pharmacology. 8: 442. PMID 28729837 DOI: 10.3389/Fphar.2017.00442 |
0.365 |
|
| 2016 |
Shenoy PA, Kuo A, Vetter I, Smith MT. The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats. Frontiers in Pharmacology. 7: 286. PMID 27630567 DOI: 10.3389/Fphar.2016.00286 |
0.309 |
|
| 2016 |
Pippin AB, Mohd Arshad ZH, Voll RJ, Nye JA, Ghassabian S, Williams CM, Mancini A, Liotta DC, Smith MT, Goodman MM. In Vitro Metabolic Stability and in Vivo Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats. Acs Medicinal Chemistry Letters. 7: 563-7. PMID 27326327 DOI: 10.1021/Acsmedchemlett.5B00410 |
0.321 |
|
| 2016 |
Muralidharan A, Kuo A, Jacob M, Lourdesamy JS, Carvalho LM, Nicholson JR, Corradini L, Smith MT. Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience. 10: 88. PMID 27242458 DOI: 10.3389/Fnbeh.2016.00088 |
0.343 |
|
| 2016 |
Smith MT, Anand P, Rice AS. Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies. Pain. 157: S33-41. PMID 26785154 DOI: 10.1097/J.Pain.0000000000000369 |
0.354 |
|
| 2015 |
Khan N, Gordon R, Woodruff TM, Smith MT. Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MS-neuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signaling in the dorsal horn of the spinal cord. Pharmacology Research & Perspectives. 3: e00137. PMID 26171221 DOI: 10.1002/Prp2.137 |
0.324 |
|
| 2015 |
Huang LY, Tsui DY, Williams CM, Wyse BD, Smith MT. The Furoxan Nitric Oxide Donor, PRG150, Evokes Dose-Dependent Analgesia in a Rat Model of Painful Diabetic Neuropathy (PDN). Clinical and Experimental Pharmacology & Physiology. PMID 26119582 DOI: 10.1111/1440-1681.12442 |
0.372 |
|
| 2015 |
Smith MT, Wyse BD, Edwards SR, El-Tamimy M, Gaetano G, Gavin P. Topical Application of a Novel Oxycodone Gel Formulation (Tocopheryl Phosphate Mixture) in a Rat Model of Peripheral Inflammatory Pain Produces Localized Pain Relief Without Significant Systemic Exposure. Journal of Pharmaceutical Sciences. 104: 2388-96. PMID 25995048 DOI: 10.1002/Jps.24502 |
0.393 |
|
| 2015 |
Han FY, Thurecht KJ, Lam AL, Whittaker AK, Smith MT. Novel Polymeric Bioerodable Microparticles for Prolonged-Release Intrathecal Delivery of Analgesic Agents for Relief of Intractable Cancer-Related Pain. Journal of Pharmaceutical Sciences. 104: 2334-44. PMID 25990226 DOI: 10.1002/Jps.24497 |
0.405 |
|
| 2015 |
Rice AS, Smith MT. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain. Clinical Pharmacology and Therapeutics. 97: 128-30. PMID 25670516 DOI: 10.1002/Cpt.29 |
0.341 |
|
| 2015 |
Smith MT, Muralidharan A. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion On Therapeutic Targets. 19: 25-35. PMID 25315162 DOI: 10.1517/14728222.2014.957673 |
0.335 |
|
| 2015 |
Kuo A, Wyse BD, Meutermans W, Smith MT. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. British Journal of Pharmacology. 172: 532-48. PMID 24641546 DOI: 10.1111/Bph.12696 |
0.427 |
|
| 2014 |
Han FY, Wyse BD, Smith MT. Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain. Behavioural Pharmacology. 25: 732-40. PMID 25325291 DOI: 10.1097/Fbp.0000000000000090 |
0.394 |
|
| 2014 |
Khan N, Woodruff TM, Smith MT. Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. Pharmacology, Biochemistry, and Behavior. 126: 13-27. PMID 25223977 DOI: 10.1016/J.Pbb.2014.09.003 |
0.374 |
|
| 2014 |
Cai J, Song B, Cai Y, Ma Y, Lam AL, Magiera J, Sekar S, Wyse BD, Ambo A, Sasaki Y, Lazarus LH, Smith MT, Li T. Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity. Bioorganic & Medicinal Chemistry. 22: 2208-19. PMID 24613457 DOI: 10.1016/J.Bmc.2014.02.015 |
0.387 |
|
| 2014 |
Smith MT, Lau T, Wallace VC, Wyse BD, Rice AS. Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy. Behavioural Pharmacology. 25: 137-46. PMID 24525712 DOI: 10.1097/Fbp.0000000000000025 |
0.412 |
|
| 2014 |
Muralidharan A, Wyse BD, Smith MT. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain. Pain Medicine (Malden, Mass.). 15: 93-110. PMID 24433468 DOI: 10.1111/Pme.12258 |
0.37 |
|
| 2014 |
Khan N, Smith MT. Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology. 22: 1-22. PMID 24234347 DOI: 10.1007/S10787-013-0195-3 |
0.322 |
|
| 2014 |
Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. The Journal of Pharmacology and Experimental Therapeutics. 348: 217-26. PMID 24227768 DOI: 10.1124/Jpet.113.209478 |
0.316 |
|
| 2014 |
Tompkins DA, Smith MT, Bigelow GE, Moaddel R, Venkata SL, Strain EC. The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males. The Clinical Journal of Pain. 30: 36-45. PMID 23446076 DOI: 10.1097/AJP.0b013e3182851758 |
0.318 |
|
| 2013 |
Muralidharan A, Smith MT. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology. 21: 339-63. PMID 23918298 DOI: 10.1007/S10787-013-0183-7 |
0.335 |
|
| 2013 |
Smith MT, Woodruff TM, Wyse BD, Muralidharan A, Walther T. A small molecule angiotensin II type 2 receptor (ATâ‚‚R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Medicine (Malden, Mass.). 14: 1557-68. PMID 23742186 DOI: 10.1111/Pme.12157 |
0.339 |
|
| 2013 |
Muralidharan A, Wyse BD, Smith MT. Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacology, Biochemistry, and Behavior. 106: 33-46. PMID 23500189 DOI: 10.1016/J.Pbb.2013.02.020 |
0.4 |
|
| 2013 |
Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (ATâ‚‚R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Medicine (Malden, Mass.). 14: 692-705. PMID 23489258 DOI: 10.1111/Pme.12063 |
0.426 |
|
| 2013 |
Varamini P, Goh WH, Mansfeld FM, Blanchfield JT, Wyse BD, Smith MT, Toth I. Peripherally acting novel lipo-endomorphin-1 peptides in neuropathic pain without producing constipation. Bioorganic & Medicinal Chemistry. 21: 1898-904. PMID 23433669 DOI: 10.1016/J.Bmc.2013.01.044 |
0.457 |
|
| 2013 |
Pulman KG, Smith M, Mengozzi M, Ghezzi P, Dilley A. The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience. 233: 174-83. PMID 23262243 DOI: 10.1016/J.Neuroscience.2012.12.022 |
0.313 |
|
| 2012 |
Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, Ghassabian S, Wallis SC, Levkovich B, Pellegrino V, McGuinness S, Parke R, Gilder E, Barnett AG, Walsham J, ... ... Smith MT, et al. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. Bmc Anesthesiology. 12: 29. PMID 23190792 DOI: 10.1186/1471-2253-12-29 |
0.302 |
|
| 2012 |
Varamini P, Mansfeld FM, Blanchfield JT, Wyse BD, Smith MT, Toth I. Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation. Plos One. 7: e41909. PMID 22912681 DOI: 10.1371/Journal.Pone.0041909 |
0.419 |
|
| 2012 |
Ghassabian S, Moosavi SM, Valero YG, Shekar K, Fraser JF, Smith MT. High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 903: 126-33. PMID 22841553 DOI: 10.1016/J.Jchromb.2012.07.005 |
0.383 |
|
| 2012 |
Smith MT, Muralidharan A. Pharmacogenetics of pain and analgesia. Clinical Genetics. 82: 321-30. PMID 22779698 DOI: 10.1111/J.1399-0004.2012.01936.X |
0.34 |
|
| 2012 |
Smith MT, Moore BJ. Pregabalin for the treatment of fibromyalgia. Expert Opinion On Pharmacotherapy. 13: 1527-33. PMID 22725707 DOI: 10.1517/14656566.2012.687373 |
0.312 |
|
| 2012 |
Varamini P, Mansfeld FM, Blanchfield JT, Wyse BD, Smith MT, Toth I. Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. Journal of Medicinal Chemistry. 55: 5859-67. PMID 22680612 DOI: 10.1021/Jm300418D |
0.474 |
|
| 2012 |
Ghassabian S, Wright LA, Dejager AD, Smith MT. Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 881: 34-41. PMID 22197608 DOI: 10.1016/J.Jchromb.2011.11.031 |
0.314 |
|
| 2012 |
Shekar K, Mcdonald C, Fisquet S, Barnett A, Ghassabian S, Fung L, Roberts J, Smith M, Fraser J. Is Morphine Superior to Fentanyl for Analgesia during Extracorporeal Membrane Oxygenation in Adult Patients? Heart, Lung and Circulation. 21: S237-S238. DOI: 10.1016/J.Hlc.2012.05.585 |
0.312 |
|
| 2011 |
Muralidharan A, Smith MT. Pain, analgesia and genetics. The Journal of Pharmacy and Pharmacology. 63: 1387-400. PMID 21988420 DOI: 10.1111/J.2042-7158.2011.01340.X |
0.334 |
|
| 2011 |
Otto KJ, Wyse BD, Cabot PJ, Smith MT. Insulin implants prevent the temporal development of mechanical allodynia and opioid hyposensitivity for 24-wks in streptozotocin (STZ)-diabetic Wistar rats. Pain Medicine (Malden, Mass.). 12: 782-93. PMID 21481170 DOI: 10.1111/J.1526-4637.2011.01102.X |
0.319 |
|
| 2011 |
Gray P, Kirby J, Smith MT, Cabot PJ, Williams B, Doecke J, Cramond T. Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial. Pain. 152: 1279-88. PMID 21398038 DOI: 10.1016/J.Pain.2011.01.055 |
0.677 |
|
| 2011 |
Otto KJ, Wyse BD, Cabot PJ, Smith MT. Longitudinal study of painful diabetic neuropathy in the Zucker diabetic fatty rat model of type 2 diabetes: impaired basal G-protein activity appears to underpin marked morphine hyposensitivity at 6 months. Pain Medicine (Malden, Mass.). 12: 437-50. PMID 21332939 DOI: 10.1111/J.1526-4637.2011.01067.X |
0.356 |
|
| 2010 |
Zin CS, Nissen LM, O'Callaghan JP, Moore BJ, Smith MT. Preliminary study of the plasma and cerebrospinal fluid concentrations of IL-6 and IL-10 in patients with chronic pain receiving intrathecal opioid infusions by chronically implanted pump for pain management. Pain Medicine (Malden, Mass.). 11: 550-61. PMID 20202139 DOI: 10.1111/J.1526-4637.2010.00821.X |
0.362 |
|
| 2010 |
Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. The Journal of Pain : Official Journal of the American Pain Society. 11: 462-71. PMID 19962354 DOI: 10.1016/J.Jpain.2009.09.003 |
0.361 |
|
| 2009 |
Brust A, Palant E, Croker DE, Colless B, Drinkwater R, Patterson B, Schroeder CI, Wilson D, Nielsen CK, Smith MT, Alewood D, Alewood PF, Lewis RJ. chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. Journal of Medicinal Chemistry. 52: 6991-7002. PMID 19860431 DOI: 10.1021/Jm9003413 |
0.32 |
|
| 2009 |
Hemstapat K, Le L, Edwards SR, Smith MT. Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin A(2-17) following spinal and supraspinal routes of administration. Pharmacology, Biochemistry, and Behavior. 93: 498-505. PMID 19580825 DOI: 10.1016/J.Pbb.2009.06.016 |
0.419 |
|
| 2009 |
South SM, Edwards SR, Smith MT. Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. Clinical and Experimental Pharmacology & Physiology. 36: 20-8. PMID 18671713 DOI: 10.1111/J.1440-1681.2008.05019.X |
0.417 |
|
| 2008 |
Smith MT. Differences between and combinations of opioids re-visited. Current Opinion in Anaesthesiology. 21: 596-601. PMID 18784485 DOI: 10.1097/Aco.0B013E32830A4C4A |
0.423 |
|
| 2008 |
Zin CS, Nissen LM, Smith MT, O'Callaghan JP, Moore BJ. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. Cns Drugs. 22: 417-42. PMID 18399710 DOI: 10.2165/00023210-200822050-00005 |
0.352 |
|
| 2008 |
Chan S, Edwards SR, Wyse BD, Smith MT. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Clinical and Experimental Pharmacology & Physiology. 35: 295-302. PMID 17973932 DOI: 10.1111/J.1440-1681.2007.04821.X |
0.324 |
|
| 2007 |
Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 132: 289-300. PMID 17467904 DOI: 10.1016/J.Pain.2007.03.022 |
0.671 |
|
| 2007 |
Edwards SR, Mather LE, Smith MT. Studies with ketamine and alfentanil following Freund's complete adjuvant-induced inflammation in rats. Clinical and Experimental Pharmacology & Physiology. 34: 414-20. PMID 17439409 DOI: 10.1111/J.1440-1681.2007.04581.X |
0.39 |
|
| 2007 |
Edwards SR, Smith MT. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 848: 264-70. PMID 17098487 DOI: 10.1016/J.Jchromb.2006.10.039 |
0.322 |
|
| 2007 |
Otto K, Wyse B, South S, Cabot P, Smith M. 162 INFLUENCE OF DIET ON TEMPORAL DEVELOPMENT OF TACTILE ALLODYNIA AND OPIOID HYPOSENSITIVITY FOR 22-WEEKS IN THE ZUCKER DIABETIC FATTY RAT European Journal of Pain. 11: S70-S70. DOI: 10.1016/J.Ejpain.2007.03.177 |
0.329 |
|
| 2005 |
Nielsen CK, Lewis RJ, Alewood D, Drinkwater R, Palant E, Patterson M, Yaksh TL, McCumber D, Smith MT. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain. 118: 112-24. PMID 16154696 DOI: 10.1016/J.Pain.2005.08.002 |
0.387 |
|
| 2005 |
Huang L, Edwards SR, Smith MT. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes. Pharmaceutical Research. 22: 1489-98. PMID 16132361 DOI: 10.1007/S11095-005-6154-Y |
0.342 |
|
| 2005 |
Ladd LA, Kam PC, Williams DB, Wright AWE, Smith MT, Mather LE. Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions British Journal of Clinical Pharmacology. 59: 524-535. PMID 15842550 DOI: 10.1111/J.1365-2125.2005.02368.X |
0.397 |
|
| 2005 |
Smith MT, de la Iglesia FA. Co-administration of oxycodone and morphine and analgesic synergy re-examined. British Journal of Clinical Pharmacology. 59: 486-7; author reply . PMID 15801946 DOI: 10.1111/J.1365-2125.2005.02345_1.X |
0.485 |
|
| 2005 |
Edwards SR, Smith MT. Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 814: 241-9. PMID 15639445 DOI: 10.1016/J.Jchromb.2004.10.035 |
0.389 |
|
| 2004 |
Leck KJ, Bartlett SE, Smith MT, Megirian D, Holgate J, Powell KL, Matthaei KI, Hendry IA. Deletion of guanine nucleotide binding protein alpha z subunit in mice induces a gene dose dependent tolerance to morphine. Neuropharmacology. 46: 836-46. PMID 15033343 DOI: 10.1016/J.Neuropharm.2003.11.024 |
0.557 |
|
| 2003 |
Hemstapat K, Smith SA, Monteith GR, Smith MT. The neuroexcitatory morphine metabolite, morphine-3-glucuronide (M3G), is not neurotoxic in primary cultures of either hippocampal or cerebellar granule neurones. Pharmacology & Toxicology. 93: 197-200. PMID 14629745 DOI: 10.1034/J.1600-0773.2003.930408.X |
0.373 |
|
| 2003 |
Hemstapat K, Monteith GR, Smith D, Smith MT. Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones. Anesthesia and Analgesia. 97: 494-505, table of co. PMID 12873944 DOI: 10.1213/01.Ane.0000059225.40049.99 |
0.376 |
|
| 2002 |
Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain. 96: 119-27. PMID 11932068 DOI: 10.1016/S0304-3959(01)00436-5 |
0.345 |
|
| 2001 |
Nissen LM, Tett SE, Cramond T, Williams B, Smith MT. Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital. British Journal of Clinical Pharmacology. 52: 693-8. PMID 11736881 DOI: 10.1046/J.0306-5251.2001.01502.X |
0.722 |
|
| 2001 |
Wright AWE, Mather LE, Smith MT. Hydromorphone-3-glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronide Life Sciences. 69: 409-420. PMID 11459432 DOI: 10.1016/S0024-3205(01)01133-X |
0.408 |
|
| 2001 |
South SM, Wright AWE, Lau M, Mather LE, Smith MT. Sex-related differences in antinociception and tolerance development following chronic intravenous infusion of morphine in the rat: Modulatory role of testosterone via morphine clearance Journal of Pharmacology and Experimental Therapeutics. 297: 446-457. PMID 11259573 |
0.331 |
|
| 2001 |
Smith MT, South SM. The role of morphine-6-glucuronide (M6G) in pain control Pain Reviews. 8: 171-191. DOI: 10.1191/0968130201Pr183Ra |
0.48 |
|
| 2001 |
Smith MT, Ross FB, Nielsen CK, Saini K. Oxycodone has a distinctly different pharmacology from morphine European Journal of Pain. 5: 135-136. DOI: 10.1053/Eujp.2001.0301 |
0.472 |
|
| 2000 |
Nielsen CK, Ross FB, Smith MT. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the dark agouti rat Journal of Pharmacology and Experimental Therapeutics. 295: 91-99. PMID 10991965 |
0.354 |
|
| 2000 |
Smith MT. Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites Clinical and Experimental Pharmacology and Physiology. 27: 524-528. PMID 10874511 DOI: 10.1046/J.1440-1681.2000.03290.X |
0.481 |
|
| 2000 |
Ross FB, Wallis SC, Smith MT. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats Pain. 84: 421-428. PMID 10666549 DOI: 10.1016/S0304-3959(99)00230-4 |
0.472 |
|
| 2000 |
Smith MT, Nielsen CK, Lim-Fraser MYC, Wright AWE, Lau M. Systemic coadministration of chloramphenicol with intravenous but not intracerebroventricular morphine markedly increases morphine antinociception and delays development of antinociceptive tolerance in rats Drug Metabolism and Disposition. 28: 236-244. PMID 10640523 |
0.357 |
|
| 1999 |
Keates HL, Cramond T, Smith MT. Intraarticular and periarticular opioid binding in inflamed tissue in experimental canine arthritis. Anesthesia and Analgesia. 89: 409-15. PMID 10439757 DOI: 10.1097/00000539-199908000-00030 |
0.702 |
|
| 1999 |
Halliday AJ, Bartlett SE, Colditz P, Smith MT. Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide. Life Sciences. 65: 225-36. PMID 10416828 DOI: 10.1016/S0024-3205(99)00239-8 |
0.581 |
|
| 1999 |
Smith MT, Wright AW, Williams BE, Stuart G, Cramond T. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesthesia and Analgesia. 88: 109-16. PMID 9895076 DOI: 10.1097/00000539-199901000-00021 |
0.728 |
|
| 1998 |
South SM, Smith MT. Apparent insensitivity of the hotplate latency test for detection of antinociception following intraperitoneal, intravenous or intracerebroventricular M6G administration to rats Journal of Pharmacology and Experimental Therapeutics. 286: 1326-1332. PMID 9732396 |
0.335 |
|
| 1998 |
Wright AWE, Nocente ML, Smith MT. Hydromorphone-3-glucuronide: Biochemical synthesis and preliminary pharmacological evaluation Life Sciences. 63: 401-411. PMID 9714427 DOI: 10.1016/S0024-3205(98)00288-4 |
0.339 |
|
| 1998 |
Wright AW, Lawrence JA, Iu M, Cramond T, Smith MT. Solid-phase extraction method with high-performance liquid chromatography and electrochemical detection for the quantitative analysis of oxycodone in human plasma. Journal of Chromatography. B, Biomedical Sciences and Applications. 712: 169-75. PMID 9698239 DOI: 10.1016/S0378-4347(98)00146-7 |
0.646 |
|
| 1998 |
Smith GD, Smith MT. The excitatory behavioral and antianalgesic pharmacology of normorphine- 3-glucuronide after intracerebroventricular administration to rats Journal of Pharmacology and Experimental Therapeutics. 285: 1157-1162. PMID 9618418 |
0.354 |
|
| 1998 |
Wright AWE, Smith MT. Improved one-step solid-phase extraction method for morphine, morphine- 3-glucuronide, and morphine-6-glucuronide from plasma and quantitation using high-performance liquid chromatography with electrochemical detection Therapeutic Drug Monitoring. 20: 215-218. PMID 9558137 DOI: 10.1097/00007691-199804000-00013 |
0.398 |
|
| 1998 |
Preechagoon D, Smith MT, Prankerd RJ. Investigation of the antinociceptive efficacy and relative potency of extended duration injectable 3-acylmorphine-6-sulfate prodrugs in rats International Journal of Pharmaceutics. 163: 191-201. DOI: 10.1016/S0378-5173(97)00380-3 |
0.31 |
|
| 1997 |
Cabot PJ, Cramond T, Smith MT. Morphine has a dual concentration-dependent effect on K(+)-evoked substance P release from rat peripheral airways. Pulmonary Pharmacology & Therapeutics. 10: 215-21. PMID 9695145 DOI: 10.1006/Pupt.1997.0094 |
0.696 |
|
| 1997 |
Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated Pain. 73: 151-157. PMID 9415500 DOI: 10.1016/S0304-3959(97)00093-6 |
0.438 |
|
| 1997 |
Smith GD, Prankerd RJ, Smith MT. Biochemical synthesis, purification and preliminary pharmacological evaluation of normorphine-3-glucuronide Life Sciences. 61: 95-104. PMID 9217268 DOI: 10.1016/S0024-3205(97)00364-0 |
0.43 |
|
| 1996 |
Cabot PJ, Cramond T, Smith MT. Quantitative autoradiography of peripheral opioid binding sites in rat lung. European Journal of Pharmacology. 310: 47-53. PMID 8880066 DOI: 10.1016/0014-2999(96)00363-9 |
0.692 |
|
| 1996 |
Bartlett SE, Smith MT. Effects of morphine-3-glucuronide and morphine on the K+-evoked release of [3H]-glutamic acid and [14C]-gamma-aminobutyric acid from rat brain synaptosomes. Life Sciences. 58: 447-54. PMID 8594310 DOI: 10.1016/0024-3205(95)02310-0 |
0.523 |
|
| 1995 |
Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesthesia and Analgesia. 80: 296-302. PMID 7818116 DOI: 10.1097/00000539-199502000-00016 |
0.696 |
|
| 1995 |
Bartlett SE, Smith MT. The apparent affinity of morphine-3-glucuronide at mu1-opioid receptors results from morphine contamination: demonstration using HPLC and radioligand binding. Life Sciences. 57: 609-15. PMID 7623628 DOI: 10.1016/0024-3205(95)00311-S |
0.593 |
|
| 1995 |
Smith GD, Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat Pain. 62: 51-60. PMID 7478708 DOI: 10.1016/0304-3959(94)00228-7 |
0.46 |
|
| 1994 |
Kim Pei Leow, Smith MT. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats Life Sciences. 54: 1229-1236. PMID 8164504 DOI: 10.1016/0024-3205(94)00849-3 |
0.463 |
|
| 1994 |
Bartlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sciences. 54: 687-94. PMID 8107513 DOI: 10.1016/0024-3205(94)00552-4 |
0.739 |
|
| 1994 |
Wright AW, Watt JA, Kennedy M, Cramond T, Smith MT. Quantitation of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in plasma and cerebrospinal fluid using solid-phase extraction and high-performance liquid chromatography with electrochemical detection. Therapeutic Drug Monitoring. 16: 200-8. PMID 8009570 DOI: 10.1097/00007691-199404000-00016 |
0.719 |
|
| 1994 |
Bartlett SE, Dodd PR, Smith MT. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacology & Toxicology. 75: 73-81. PMID 7971741 DOI: 10.1111/J.1600-0773.1994.Tb00327.X |
0.597 |
|
| 1994 |
Cabot PJ, Dodd PR, Cramond T, Smith MT. Characterization of non-conventional opioid binding sites in rat and human lung. European Journal of Pharmacology. 268: 247-55. PMID 7957646 DOI: 10.1016/0922-4106(94)90195-3 |
0.681 |
|
| 1994 |
Smith M, Cramond T. Comments on Goucke et al., PAIN, 56 (1994) 145-149. Pain. 59: 155-6. PMID 7854800 DOI: 10.1016/0304-3959(94)90065-5 |
0.636 |
|
| 1993 |
Leow KP, Wright AW, Cramond T, Smith MT. Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Therapeutic Drug Monitoring. 15: 440-7. PMID 8249052 DOI: 10.1097/00007691-199310000-00014 |
0.672 |
|
| 1992 |
Leow KP, Smith MT, Watt JA, Williams BE, Cramond T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Therapeutic Drug Monitoring. 14: 479-84. PMID 1485370 DOI: 10.1097/00007691-199212000-00008 |
0.672 |
|
| 1992 |
Cramond T, Smith MT, Watt JA. Comments on Gong et al., PAIN, 48 (1992) 249-255. Pain. 51: 124-5. PMID 1454398 DOI: 10.1016/0304-3959(92)90022-4 |
0.636 |
|
| 1992 |
Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clinical Pharmacology and Therapeutics. 52: 487-95. PMID 1424423 DOI: 10.1038/Clpt.1992.176 |
0.694 |
|
| 1991 |
Smith MT, Watt JA, Mapp GP, Cramond T. Quantitation of oxycodone in human plasma using high-performance liquid chromatography with electrochemical detection. Therapeutic Drug Monitoring. 13: 126-30. PMID 2053119 DOI: 10.1097/00007691-199103000-00007 |
0.669 |
|
| 1990 |
Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide--a potent antagonist of morphine analgesia. Life Sciences. 47: 579-85. PMID 2402182 DOI: 10.1016/0024-3205(90)90619-3 |
0.724 |
|
| 1990 |
Cheng WS, Murphy TL, Smith MT, Cooksley WG, Halliday JW, Powell LW. Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clinical Pharmacology and Therapeutics. 47: 516-24. PMID 2328560 DOI: 10.1038/Clpt.1990.66 |
0.339 |
|
| 1990 |
Smith MT, Cramond T. Morphine-3-Glucuronide — A potent antagonist of morphine analgesia Pain. 41: S186. DOI: 10.1016/0304-3959(90)92509-O |
0.706 |
|
| 1990 |
Cramond T, Smith M, Watt J, Kute S, Mapp G. High Performance Liquid Chromatography (HPLC) determination of oxycodone in human plasma after oral, rectal and intravenous routes Pain. 41: S176. DOI: 10.1016/0304-3959(90)92488-C |
0.647 |
|
| 1985 |
Brandon RA, Eadie MJ, Smith MT. A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. Therapeutic Drug Monitoring. 7: 216-21. PMID 4024217 DOI: 10.1097/00007691-198506000-00014 |
0.357 |
|
| 1984 |
Smith MT, Heazlewood V, Eadie MJ, Brophy TO, Tyrer JH. Pharmacokinetics of midazolam in the aged. European Journal of Clinical Pharmacology. 26: 381-8. PMID 6734699 DOI: 10.1007/Bf00548771 |
0.305 |
|
| 1981 |
Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology. 19: 271-8. PMID 6116606 DOI: 10.1007/Bf00562804 |
0.354 |
|
| 1980 |
Smith MT, Evans LE, Eadie MJ, Tyrer JH. Pharmacokinetics of prazepam in man. European Journal of Clinical Pharmacology. 16: 141-7. PMID 387419 DOI: 10.1007/Bf00563121 |
0.307 |
|
| Show low-probability matches. |